RegulatoryCompany release

REGENXBIO targets Q1 2027 RGX-202 BLA as RGX-121 clinical hold continues

🇺🇸 REGENXBIO Inc. (RGNX) · Thu 05 Nov 2026

The gene therapy developer plans a pre-BLA meeting in Q4 2026 for its Duchenne candidate, while the FDA hold on its MPS II programme remains in place.

REGENXBIO said on 5 November, alongside its third-quarter 2026 results, that it expects to submit a biologics licence application (BLA) for RGX-202, its Duchenne muscular dystrophy gene therapy, in the first quarter of 2027. The company intends to seek accelerated approval. A pre-BLA meeting with the US Food and Drug Administration is planned for the fourth quarter of 2026.

In ophthalmology, REGENXBIO expects pivotal data in the fourth quarter of 2026 for subretinally delivered sura-vec in wet age-related macular degeneration (wet AMD). The programme is run with AbbVie.

The update was less favourable for RGX-121, the company's candidate for mucopolysaccharidosis type II (MPS II). The FDA clinical hold, imposed in August after asymptomatic findings on spine MRI in five participants, is still in force. The company did not set out a timetable for lifting it in the information provided.

On financials, REGENXBIO reported a net loss of $40.7 million for the quarter. It said its cash runway extends into late Q4 2027.

What it means for your team

  • The pre-BLA meeting in Q4 2026 is the next regulatory milestone to watch for RGX-202; accelerated approval would typically rely on a surrogate or intermediate endpoint, which the FDA will scrutinise.
  • The continuing RGX-121 hold, triggered by asymptomatic spine MRI findings, shows the FDA's sensitivity to imaging safety signals in gene therapy trials, which is relevant for safety monitoring design.
  • Pivotal sura-vec wet AMD data due in Q4 2026 could shape the timing of later filings, with AbbVie as partner.
  • A cash runway into late Q4 2027 covers the planned RGX-202 filing window but leaves limited headroom if timelines slip.

Company's press release (SEC filing): REGENXBIO Inc. ↗

Article written by VigiEye from the official source (REGENXBIO Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →